Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Angiogenesis Inhibitors in Personalized Combination Regimens for the Treatment of Advanced Refractory Cancers.
Crook T, Patil D, Nagarkar R, Gaya A, Plowman N, Limaye S, Srivastava N, Akolkar D, Ranade A, Bhatt A, Datta V, Bose C, Apurwa S, Patil S, Kumar P, Srinivasan A, Datar R. Crook T, et al. Among authors: limaye s. Front Mol Med. 2021 Sep 20;1:749283. doi: 10.3389/fmmed.2021.749283. eCollection 2021. Front Mol Med. 2021. PMID: 39087078 Free PMC article.
Landscape of Clinically Relevant Genomic Alterations in the Indian Non-small Cell Lung Cancer Patients.
Jha P, Joshi A, Mishra R, Biswal RP, Kulkarni PM, Limaye S, Babu G, Batra U, Malik P, Kumar R, Shah M, Menon N, Rauthan A, Kuriakose M, Ramachandran V, Noronha V, Kumar P, Prabhash K. Jha P, et al. Among authors: limaye s. Clin Lung Cancer. 2024 Dec;25(8):e420-e430.e20. doi: 10.1016/j.cllc.2024.07.011. Epub 2024 Jul 22. Clin Lung Cancer. 2024. PMID: 39129089
Novel Effective Therapeutic Regimen for Recurrent/Metastatic Head and Neck Squamous Cell Cancer: Concurrent Triple Oral Metronomic Chemotherapy and Immunotherapy.
Limaye S, Menon M, Singh S, Kataria P, Shreenivas AV, Datar R, Patil D, Kumar P, Shah N, Sheth H, Sneha S, Madre C, Deshpande R, Menon NK, Dandekar P, Haribhakti V. Limaye S, et al. J Immunother Precis Oncol. 2024 Aug 19;7(3):171-177. doi: 10.36401/JIPO-24-1. eCollection 2024 Aug. J Immunother Precis Oncol. 2024. PMID: 39220001 Free PMC article. No abstract available.
Addendum: Liquid biopsy and multi-analyte testing guided treatment of HER2 positive periampullary adenocarcinoma with durable complete response after trastuzumab based therapy.
Nagarkar R, Patil D, Limaye S, Devhare P, Ghaisas A, Srivastava N, Apurwa S, Patil S, John J, Raazi Z, Shreenivas A, Sambath J, Srinivasan A, Kumar P, Akolkar D, Datar R. Nagarkar R, et al. Among authors: limaye s. Oncotarget. 2022 Nov 2;13:1215. doi: 10.18632/oncotarget.28296. Oncotarget. 2022. PMID: 36342460 Free PMC article. No abstract available.
Dynamic changes in tumor profiling reveal intra- and inter-tumoral heterogeneity focused on an uncharacterized HER2 mutation: a case report of a young breast cancer patient.
Schaffrin-Nabe D, Josten-Nabe A, Tannapfel A, Uhl W, Garmer M, Kurzrock R, Crook T, Limaye S, Schuster S, Patil D, Schaffrin M, Mokbel K, Voigtmann R. Schaffrin-Nabe D, et al. Among authors: limaye s. Front Oncol. 2024 May 3;14:1395618. doi: 10.3389/fonc.2024.1395618. eCollection 2024. Front Oncol. 2024. PMID: 38764581 Free PMC article.
192 results